Medical weight management | New York
Wegovy tablets are FDA-approved oral semaglutide for adult weight management and qualifying adult cardiovascular risk reduction. They are not the same product as Ozempic tablets, and the tablet does not carry the Wegovy injection’s MASH indication.
The tablets deliver semaglutide through an oral absorption formulation. Food, drinks, and other medicines can affect absorption, so the morning instructions matter. Tablet milligrams do not match injection milligrams.
The tablet’s approved uses are for adults. The pediatric obesity indication belongs to Wegovy injection, not tablets. A clinician reviews weight-related conditions, safety, pregnancy plans, and whether daily fasting instructions are realistic.
Take the prescribed tablet in the morning on an empty stomach with no more than four ounces of water. Swallow it whole. Wait at least 30 minutes before food, other drinks, or oral medicines. The labeled escalation moves through 1.5, 4, and 9 mg to 25 mg daily over successive 30-day steps. The prescriber decides how to apply the schedule and any switch.
Bring your weight and treatment history, medicines and supplements, relevant glucose, kidney, and lipid results, and the exact product you have used before. Mention previous side effects, eye disease, eating difficulties, and pregnancy plans. If insurance denied treatment, bring the denial and plan details.
Review a personal or family history of medullary thyroid cancer, MEN 2, severe stomach-emptying problems, pancreatitis, gallbladder disease, allergies, and pregnancy plans before treatment. Nausea, vomiting, constipation, or diarrhea can occur. Persistent severe abdominal pain or inability to keep fluids down needs emergency department assessment now. Call 911 for breathing difficulty, a severe allergic reaction, loss of consciousness or unsafe travel. Tell the anesthesia team about treatment before a procedure. Do not combine GLP-1 medicines or change the dose yourself. Breastfeeding is not recommended during Wegovy tablet treatment. Discuss stopping at least two months before planned pregnancy for weight or cardiovascular treatment.
Review weight trend, appetite, food and fluid intake, bowel symptoms, and treatment tolerability. Check glucose and adjust other diabetes medicines with the prescriber when relevant. Agree on how to contact the team between visits and what to do if a refill is delayed. Continued treatment depends on benefit, safety, access, and your goals.
Confirm the exact service, clinician, formulation, appointment, and refill route before booking. The evaluation, tests, medicine, administration, and follow-up may have separate costs and benefits. Ask for current estimates and required records. An FDA-approved drug or a clinic address does not establish pharmacy stock, onsite treatment, coverage, or a prescription. If access changes, contact the treating team before interrupting treatment.
Wegovy tablets are FDA-approved oral semaglutide for adult weight management and qualifying adult cardiovascular risk reduction. They are not the same product as Ozempic tablets, and the tablet does not carry the Wegovy injection’s MASH indication. The tablet’s approved uses are for adults. The pediatric obesity indication belongs to Wegovy injection, not tablets. A clinician reviews weight-related conditions, safety, pregnancy plans, and whether daily fasting instructions are realistic.
Yes. Novo Nordisk launched Wegovy tablets in the United States on January 5, 2026. As of October 9, 2026, they are a marketed prescription product with adult indications. Confirm that the pharmacy can supply your prescribed tablet strength and arrange ongoing refills. The tablet and injection have different doses and approved uses; commercial launch does not guarantee a prescription or supply at a particular Nao clinic.
Take the prescribed tablet in the morning on an empty stomach with no more than four ounces of water. Swallow it whole. Wait at least 30 minutes before food, other drinks, or oral medicines. The labeled escalation moves through 1.5, 4, and 9 mg to 25 mg daily over successive 30-day steps. The prescriber decides how to apply the schedule and any switch.
Take the prescribed tablet in the morning on an empty stomach with no more than four ounces of water. Swallow it whole. Wait at least 30 minutes before food, other drinks, or oral medicines. The labeled escalation moves through 1.5, 4, and 9 mg to 25 mg daily over successive 30-day steps. The prescriber decides how to apply the schedule and any switch. This is label information, not an individualized prescription. The prescriber must set your dose.
The tablet’s approved uses are for adults. The pediatric obesity indication belongs to Wegovy injection, not tablets. A clinician reviews weight-related conditions, safety, pregnancy plans, and whether daily fasting instructions are realistic.
No. The Wegovy MASH indication belongs to the injection. Wegovy tablets have adult weight and qualifying cardiovascular indications, not the injection’s MASH indication. Product choice must follow the exact formulation’s label.
A switch needs review of the exact product, dose, time on treatment, response, side effects, nutrition, and access. A plateau alone does not mean you must change medicines. The prescriber sets a transition and titration plan. Do not overlap products or convert milligrams yourself.
As of October 9, 2026, the manufacturer advertises self-pay prices of $149 for 30 tablets at 1.5 mg, $199 at 4 mg, and $299 at 9 or 25 mg. The labeled adult maintenance dose is 25 mg daily, so the lowest advertised price is a starting-strength price. Confirm current eligibility, pharmacy charges and the cost at your prescribed strength. The medicine price does not include a medical visit or laboratory tests.
Wegovy 25 mg tablets have evidence for adult weight reduction from a 64-week placebo-controlled trial. That study did not directly compare the tablets with Wegovy injection, so separate trial averages cannot prove equal results for you. The current injection label includes several presentations and doses, including 7.2 mg for selected adults, which should not be treated as one comparison group. Your response, side effects and ability to follow the tablet’s fasting instructions matter. Tablet and injection milligrams are not equivalent. Any switch needs a prescribed schedule.
The storage rules depend on the product. Keep unused single-dose injection pens or syringes refrigerated at 2–8°C (36–46°F). Before cap removal, they may be kept at 8–30°C (46–86°F) for up to 28 days under the label’s instructions. FlexTouch pens are refrigerated before first use. After first use, its patient instructions allow up to 56 days refrigerated or at 20–25°C (68–77°F). Keep the pen capped, with the needle removed. Do not freeze any injection or use one that has frozen. Wegovy tablets stay in their original bottle at room temperature, protected from moisture. Follow the exact package instructions and ask the pharmacist about uncertain temperature exposure.
Yes, approved oral semaglutide products have clinical evidence for their labeled uses. Wegovy tablets are approved for adult weight management and qualifying cardiovascular risk reduction. Ozempic tablets/Rybelsus are separate diabetes products. That does not establish benefit for every compounded or unapproved oral preparation. Absorption depends on following the exact product’s instructions. Wegovy tablets are taken whole on an empty stomach in the morning with no more than four ounces of water, followed by at least 30 minutes before food, drinks or other oral medicines. Do not convert an injection dose to tablet milligrams.
The clinician should confirm the adult indication, cardiovascular and weight history, current medicines, diabetes and eye history, gastrointestinal and gallbladder concerns, pregnancy plans, procedure plans, contraindications, and whether the daily fasting routine is practical.
Take the tablet once daily on an empty stomach in the morning with up to four ounces of water. Swallow it whole, then wait at least 30 minutes before eating, drinking, or taking other oral medicines. The label escalates through 1.5 mg, 4 mg, and 9 mg to a 25 mg maintenance dose.
Follow-up should address response, gastrointestinal effects, hydration, kidney concerns, blood glucose when relevant, retinopathy history, heart rate, hypersensitivity, gallbladder or pancreatitis symptoms, and absorption of important oral medicines.
The clinician should confirm the adult indication, cardiovascular and weight history, current medicines, diabetes and eye history, gastrointestinal and gallbladder concerns, pregnancy plans, procedure plans, contraindications, and whether the daily fasting routine is practical.
Follow-up should address response, gastrointestinal effects, hydration, kidney concerns, blood glucose when relevant, retinopathy history, heart rate, hypersensitivity, gallbladder or pancreatitis symptoms, and absorption of important oral medicines.
Before starting Wegovy tablets, discuss adult eligibility, fasting instructions, other medicines, any switch from another formulation, pharmacy supply, costs and follow-up. Follow the exact tablet instructions from your prescriber.
An evaluation may lead to another medicine, more testing, a referral, or no medication change.
The health plan and dispensing pharmacy make coverage and fulfillment decisions. Prior authorization may be required.
The clinic cards below show places to start an evaluation. They do not prove that a product is stocked, dispensed, taught, or administered at that site.
Bronx
932 E 174th St, Bronx, NY 10460
Choose a nearby clinic for an evaluation and care coordination. Before traveling, confirm the appointment type and any testing, medication teaching or treatment you need.
Queens
37-15 23rd Ave, Astoria, NY 11105
Choose a nearby clinic for an evaluation and care coordination. Before traveling, confirm the appointment type and any testing, medication teaching or treatment you need.
Bronx
2063A Bartow Ave, Bronx, NY 10475
Choose a nearby clinic for an evaluation and care coordination. Before traveling, confirm the appointment type and any testing, medication teaching or treatment you need.
Brooklyn
341 Eastern Pkwy, Brooklyn, NY 11216
Choose a nearby clinic for an evaluation and care coordination. Before traveling, confirm the appointment type and any testing, medication teaching or treatment you need.
Long Island
232 W Old Country Rd, Hicksville, NY 11801
Choose a nearby clinic for an evaluation and care coordination. Before traveling, confirm the appointment type and any testing, medication teaching or treatment you need.
Queens
80-10 Northern Blvd, Jackson Heights, NY 11372
Choose a nearby clinic for an evaluation and care coordination. Before traveling, confirm the appointment type and any testing, medication teaching or treatment you need.
Queens
90-18 Sutphin Blvd, Jamaica, NY 11435
Choose a nearby clinic for an evaluation and care coordination. Before traveling, confirm the appointment type and any testing, medication teaching or treatment you need.
Queens
30-07 36th Ave, Astoria, NY 11106
Choose a nearby clinic for an evaluation and care coordination. Before traveling, confirm the appointment type and any testing, medication teaching or treatment you need.
Long Island
135 Mineola Blvd, Mineola, NY 11501
Choose a nearby clinic for an evaluation and care coordination. Before traveling, confirm the appointment type and any testing, medication teaching or treatment you need.
Manhattan
259 1st Ave, New York, NY 10003
Choose a nearby clinic for an evaluation and care coordination. Before traveling, confirm the appointment type and any testing, medication teaching or treatment you need.
Brooklyn
308 Graham Ave, Brooklyn, NY 11211
Choose a nearby clinic for an evaluation and care coordination. Before traveling, confirm the appointment type and any testing, medication teaching or treatment you need.
Review weekly injection, pediatric, Wegovy HD, and broader Wegovy questions.
Explore Nao Medical's broader weight-management program and treatment options.
Compare a different oral GLP-1 with different food and interaction instructions.
Review the injection-only liver indication without applying it to tablets.
Coordinate glucose-lowering treatment and hypoglycemia risk when diabetes is present.